Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Mid Cap Stocks with Best Fundamentals
Best Quarterly Growth Mid Cap Stocks
Best 1M Momentum Mid Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹36,827.2 Cr -1.4% 29.9% 50% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹429,349.0 Cr -2.8% -1% 6.7% Stock Analytics
DIVIS LABORATORIES ₹174,543.0 Cr -3.3% 0.4% -2.2% Stock Analytics
TORRENT PHARMACEUTICALS ₹147,884.0 Cr -3.1% 2.9% 36.9% Stock Analytics
CIPLA ₹111,077.0 Cr -2.7% 5.3% -6.1% Stock Analytics
DR REDDYS LABORATORIES ₹105,388.0 Cr -4.1% -3.7% 3.7% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-1.4%

29.9%

50%

SENSEX

-2.2%

-3.3%

-8.8%


You may also like the below Video Courses